[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100639397":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":10,"centralContacts":20,"locations":26,"responsibleParty":44,"collaborators":47,"id":74,"slug":75,"hasResults":76,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":76,"sex":82,"minAge":83,"maxAge":10,"enrollmentInfo":84,"targetDuration":87,"studyType":88,"phases":10,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":28,"whyStopped":10,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},{"fullName":5,"class":6},"Seoul National University Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"ARR >20 Cohort",null,"Adults with hypertension who have an aldosterone-to-renin ratio (ARR) \\>20 and meet criteria for intermediate probability of lateralizing primary aldosteronism.",[13],"Diagnostic Test: Saline Infusion Test",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":10},"DIAGNOSTIC_TEST","Saline Infusion Test","Standardized saline infusion test performed for confirmatory diagnosis of primary aldosteronism.",[9],[21],{"name":22,"role":23,"phone":24,"phoneExt":10,"email":25},"Yun Mi Choi","CONTACT","+82-31-8086-3655","ymchoi@hallym.or.kr",[27],{"facility":5,"status":28,"city":29,"state":30,"zip":31,"country":32,"countryCode":10,"cosmosGeoPoint":33,"geoPoint":38,"contacts":39},"RECRUITING","Seoul","Korea, Republic of","03080","South Korea",{"type":34,"coordinates":35},"Point",[36,37],126.9784,37.566,{"lat":37,"lon":36},[40],{"name":41,"role":23,"phone":42,"phoneExt":10,"email":43},"Jung Hee Kim","+82-02-2072-0694","jhee1@snu.ac.kr",{"type":45,"investigatorFullName":41,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Principal Investigator",[48,50,52,54,56,58,60,62,64,66,68,70,72],{"name":49,"class":6},"Gangneung Asan Hospital",{"name":51,"class":6},"Nowon Eulji Medical Center",{"name":53,"class":6},"Inha University Hospital",{"name":55,"class":6},"Asan Medical Center",{"name":57,"class":6},"Samsung Medical Center",{"name":59,"class":6},"Eunpyeong St. Mary's Hospital",{"name":61,"class":6},"Chungnam National University Hospital",{"name":63,"class":6},"Kangbuk Samsung Hospital",{"name":65,"class":6},"Ajou University School of Medicine",{"name":67,"class":6},"Hallym University Dongtan Sacred Heart Hospital",{"name":69,"class":6},"DongGuk University",{"name":71,"class":6},"Korea University Guro Hospital",{"name":73,"class":6},"Chonnam National University Hospital","100639397","study-on-cutoff-revision-effects-and-evaluation-of-nnt-in-primary-aldosteronism-100639397",false,"NCT07621458","Study on Cutoff Revision Effects and Evaluation of NNT in Primary Aldosteronism","Impact of the Revised Aldosterone-Renin Ratio (ARR) Cutoff in the 2025 Primary Aldosteronism Guideline in Real-World Practice: A Prospective Study","SCREEN-PA","Inclusion Criteria:\n\n* Adults aged 18 years or older\n* Diagnosis of hypertension or current use of antihypertensive medications\n* Plasma renin activity (PRA) ≤1 ng\u002FmL\u002Fhr\n* Plasma aldosterone concentration (PAC) ≥10 ng\u002FdL by immunoassay or ≥7.5 ng\u002FdL by liquid chromatography-tandem mass spectrometry (LC-MS\u002FMS)\n* Aldosterone-to-renin ratio (ARR) \\>20 by immunoassay or \\>15 by LC-MS\u002FMS\n* Participants meeting criteria for intermediate probability of lateralizing primary aldosteronism\n* For participants with ARR values between 20 and 30, repeat ARR measurement within 26 weeks demonstrating persistent ARR \\>20\n\nExclusion Criteria:\n\n* Current use of mineralocorticoid receptor antagonists or amiloride that cannot be discontinued according to study protocol\n* Previous adrenalectomy\n* Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \\\u003C30 mL\u002Fmin\u002F1.73 m²)\n* Pregnancy\n* Current use of combined estrogen- and progesterone-containing oral contraceptive pills or hormone replacement therapy\n* High probability primary aldosteronism defined as hypokalemia with PRA \\\u003C0.2 ng\u002FmL\u002Fhr and PAC \\>20 ng\u002FdL by immunoassay or \\>15 ng\u002FdL by LC-MS\u002FMS\n* Low probability primary aldosteronism defined as PAC \\\u003C11 ng\u002FdL by immunoassay or \\\u003C8 ng\u002FdL by LC-MS\u002FMS\n* Inability to undergo saline infusion test according to investigator judgment","ALL","18 Years",{"count":85,"type":86},150,"ESTIMATED","1 Year","OBSERVATIONAL","The goal of this observational study is to evaluate the real-world impact of applying the revised aldosterone-to-renin ratio (ARR) cutoff recommended in the 2025 primary aldosteronism guideline in adults with hypertension and biochemical findings suggestive of an intermediate probability of lateralizing primary aldosteronism (PA). The main questions it aims to answer are:\n\n* What is the number needed to test (NNT) to diagnose one case of primary aldosteronism when using the revised ARR cutoff (\\>20)?\n* What is the optimal ARR cutoff for diagnosing PA in Korean patients?\n* What is the biochemical treatment response rate at 6 months after treatment for confirmed PA?\n\nParticipants will:\n\n* Undergo standardized ARR testing after protocol-based medication adjustment and controlled sampling conditions.\n* Undergo confirmatory testing using the saline infusion test (SIT).\n* Receive standard clinical management for confirmed PA according to institutional practice.\n* Be followed for assessment of biochemical outcomes after treatment.",[91],"Primary Aldosteronism",[91,93,94,95],"Aldosterone-to-Renin Ratio","Number Needed to Test","Screening","2026-05-31",{"date":98,"type":99},"2026-06-02","ACTUAL",{"date":101,"type":99},"2026-04-01",{"date":103,"type":86},"2027-12-31",{"name":5,"class":6},1]